Immunohistochemical profiles of IDH1, MGMT and P53: Practical significance for prognostication of patients with diffuse gliomas

Neuropathology

Volumn 35, Issue 4, 2015, Pages 324-335

  Ogura, Ryosuke ^a   Tsukamoto, Yoshihiro ^a   Natsumeda, Manabu ^a   Isogawa, Mizuho ^a   Aoki, Hiroshi ^a   Kobayashi, Tsutomu ^a   Yoshida, Seiichi ^a   Okamoto, Kouichiro ^a   Takahashi, Hitoshi ^a   Fujii, Yukihiko ^a   Kakita, Akiyoshi ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Glioma; IDH1; Immunohistochemistry; MGMT; P53

Indexed keywords

DNA LIGASE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MGMT PROTEIN, HUMAN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGED; BRAIN TUMOR; FEMALE; GLIOMA; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84937191418     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12196     Document Type: Article

References (59)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System, 4th edn. Lyon: IARC, 2007.
2. Arita H, Narita Y, Fukushima S etal. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 2013; 126: 267-276.
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
4. Weller M, Stupp R, Hegi ME etal. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol 2012; 14 (Suppl 4): 100-108.
5. Molenaar RJ, Verbaan D, Lamba S etal. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 2014; 16: 1263-1273.
6. Agarwal S, Sharma MC, Jha P etal. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol 2013; 15: 718-726.
7. Capper D, Weissert S, Balss J etal. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010; 20: 245-254.
8. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J. Pitfalls in the assessment of MGMT expression and its correlation with survival in diffuse astrocytomas: proposal of feasible immunohistochemical approach. Acta Neuropathol 2008; 115: 249-259.
9. Pardo FS, Hsu DW, Zeheb R, Efird JT, Okunieff PG, Malkin DM. Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. Br J Cancer 2004; 91: 1678-1686.
10. Ogura R, Aoki H, Natsumeda M etal. Epstein-Barr virus-associated primary central nervous system cytotoxic T-cell lymphoma. Neuropathology 2013; 33: 436-441.
11. Nobusawa S, Lachuer J, Wierinckx A etal. Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol 2010; 20: 936-944.
12. 6-methylguanine-DNA-methyltransferase in a series of 100 glioblastoma patients. Cancer 2012; 118: 4201-4211.
13. 6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 2008; 32: 1220-1227.
14. 6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 2004; 70: 333-340.
15. Hegi ME, Diserens AC, Gorlia T etal. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
16. Rodriguez FJ, Scheithauer BW, Burger PC, Jenkins S, Giannini C. Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol 2010; 34: 147-160.
17. Takami H, Yoshida A, Fukushima S etal. Revisiting TP53 mutations and immunohistochemistry - a comparative study in 157 diffuse gliomas. Brain Pathol 2014. doi: 10.1111/bpa.12173 (Epub ahead of print).
18. van den Bent MJ, Dubbink HJ, Marie Y etal. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16: 1597-1604.
19. Weller M, Felsberg J, Hartmann C etal. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-5750.
20. Yan H, Parsons DW, Jin G etal. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
21. Turcan S, Rohle D, Goenka A etal. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483.
22. Arita H, Nairta Y, Matsushita Y etal. Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol 2015; 32: 22-30 (in press).
23. Felsberg J, Wolter M, Seul H etal. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 2010; 119: 501-507.
24. Chen WW, Balaj L, Liau LM etal. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids 2013; 2: e109. doi: 10.1038/mtna.2013.28.
25. Loussouarn D, Le Loupp AG, Frenel JS etal. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol 2012; 40: 2058-2062.
26. Bleeker FE, Lamba S, Leenstra S etal. IDH1 mutations at residue p.R132(IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009; 30: 7-11.
27. Horbinski C, Kofler J, Kelly LM etal. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009; 268: 1597-1604.
28. Ichimura K, Pearson DM, Kocialkowski S etal. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009; 11: 341-347.
29. Parsons DW, Jones S, Zhang X etal. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
30. Sonoda Y, Kumabe T, Nakamura T etal. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 2009; 100: 1996-1998.
31. Zhang C, Moore LM, Yung WK, Zhang W. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol 2013; 15: 1114-1126.
32. Figarella-Branger D, Maues de Paula A, Colin C, Bouvier C. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Rev Neurol (Paris) 2011; 167: 683-690.
33. Figarella-Branger D, Bouvier C, de Paula AM etal. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. J Neurooncol 2012; 110: 205-213.
34. Gupta R, Webb-Myers R, Flanagan S, Buckland ME. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 2011; 64: 835-844.
35. Dubbink HJ, Taal W, van Marion R etal. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009; 73: 1792-1795.
36. Houillier C, Wang X, Kaloshi G etal. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75: 1560-1566.
37. Mellai M, Piazzi A, Caldera V etal. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol 2011; 105: 345-357.
38. Sanson M, Marie Y, Paris S etal. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150-4154.
39. Weller M, Stupp R, Reifenberger G etal. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev Neurol 2010; 6: 39-51.
40. Wick W, Hartmann C, Engel C etal. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarvazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: 5874-5880.
41. Kitange GJ, Mladek AC, Carlson BL etal. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 2012; 18: 4070-4079.
42. 6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 2003; 22: 8835-8844.
43. Zhao W, Soejima H, Higashimoto K etal. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J Biochem 2005; 137: 431-440.
44. Kreth S, Limbeck E, Hinske LC etal. In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. Acta Neuropathol 2013; 125: 671-681.
45. Everhard S, Tost J, El Abdalaoui H etal. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 2009; 11: 348-356.
46. 6-methylguanine-DNA methyltransferase MGMT in glioblastomas. Cancer Biomark 2011; 10: 185-193.
47. Parkinson JF, Wheeler HR, Clarkson A etal. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 2008; 87: 71-78.
48. 6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol 2010; 12: 28-36.
49. Xu W, Yang H, Liu Y etal. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30.
50. Cooks T, Pateras IS, Tarcic O etal. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation associated colorectal cancer. Cancer Cell 2013; 23: 634-646.
51. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001; 61: 3573-3577.
52. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 1998; 58: 3942-3945.
53. 6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008; 18: 520-532.
54. Cao VT, Jung TY, Jung S etal. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 2009; 65: 866-875.
55. 6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol 2013; 15: 370-381.
56. Kuo LT, Tsai SY, Chang CC etal. Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors. PLoS ONE 2009; 24: e67139.
57. Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S. p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol 2010; 27: 95-101.
58. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ. Prognostic impact of TP53 mutations and p53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 2002; 8: 1117-1124.
59. Reifenberger J, Ring GU, Gies U etal. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 1996; 55: 822-831.